Andrew is a seasoned biotech executive with over 15 years of experience in drug development, corporate strategy, and leadership across the biotech and pharmaceutical industries, with a specialised focus on cellular immunotherapy.

He currently serves as Chief Business Officer at Cytospire, where he leads strategic initiatives to accelerate the company’s growth and commercial impact. Previously, Andrew held the role of Chief Business Officer at Enara Bio, where he played a key role in securing a £32.5 million Series B financing round and advancing key corporate partnerships.

Andrew has successfully led cross-functional teams across research, clinical, regulatory, commercial, and business development at companies including Immunocore, Vertex Pharmaceuticals, UCB, and GlaxoSmithKline. At Immunocore, he progressed early-phase programmes into the clinic and led a co-development partnership with Genentech. His deep expertise in oncology and regulatory affairs is matched by a strong track record in deal-making and collaboration with life science investors and global pharma partners.

Since 2023, Andrew has supported the Avigen team as a strategic advisor, providing critical input on service development, pricing strategies, and commercial positioning. He holds an MA in Molecular and Cellular Biochemistry from the University of Oxford, a PhD from University College London based on research at Cancer Research UK’s London Research Institute, and an Executive MBA with Distinction from Warwick Business School.